Company: PTPI
Filing Date: 2025-06-20
Form Type: 8-K
Source: 0001104659-25-061230
Chunk: 0

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-06-20
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

As previously disclosed, Metuchen Pharmaceuticals
LLC (“ Metuchen”), a wholly owned subsidiary of Petros Pharmaceuticals, Inc. (the “ Company”), and Vivus, Inc. (“ Vivus”)
entered into that certain termination agreement, dated as of March 31, 2025, pursuant to which, the parties mutually agreed to terminate
that certain License Agreement, dated as of September 30, 2016 (the “ Vivus License Agreement”) by and between Metuchen and
Vivus, pursuant to which the Company was entitled to purchase and receive the license for the commercialization and exploitation of Stendra®
avanafil, effective as of March 31, 2025 (the “ Vivus Termination Agreement”), subject to the survival of certain provisions
as set forth therein. As a result of the Vivus Termination Agreement, Metuchen no longer has any right in or to Vivus Technology (as defined
in the Vivus License Agreement) in the United States of America and its territories and possessions, including Puerto Rico and U. S. military
bases abroad, Canada, South America and India (the “ Licensed Territory”) and Metuchen agreed to immediately cease the development,
manufacturing and commercialization of the Company’s Stendra® product in the Licensed Territory. Metuchen further agreed to
assign any trademarks incorporating the mark “ Stendra®” to Vivus, subject to certain exceptions as set forth therein.
In furtherance of the Foreclosure Notice, and pursuant to the Termination Agreement, Metuchen agreed to transfer all completed inventory
of Stendra® and all substantially manufactured inventory of Stendra® on hand to Vivus at Metuchen’s sole expense within
30 days of the date of the Vivus Termination Agreement.

Additionally, as previously disclosed, on March
31, 2025, the board of directors (the “ Board”) of the Company determined and approved that it is advisable and in the best
interests of the Company and the Company’s stockholders to effect assignment of all of the business, assets, properties, contractual
rights, goodwill, going concern value, rights and claims (“ Assets”) of Metuchen, including Metuchen’s wholly-owned subsidiaries,
Timm Medical Technologies, Inc. (“ Timm Medical”) and Pos-T-Vac, LLC (“ PTV” and, together with Metuchen and Timm
Medical, the “ Subsidiaries”) and each of their respective Assets, for the benefit of